scanX
Home
Dr Reddys Laboratories

Dr Reddys Laboratories

1,109.50
+15.45
(1.41%)
search
Market Cap
92,582.80 Cr
EPS
335.22
PE Ratio
17.23
Dividend Yield
0.72 %
Industry
Healthcare
52 Week High
1,421.49
52 Week Low
1,020.00
PB Ratio
3.01
Debt to Equity
0.06
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from34 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+41.18 %
+41.18 %
Hold
Hold+23.53 %
+23.53 %
Sell
Sell+35.29 %
+35.29 %

Company News

View All News
Caret
neutral
Dr Reddy's Laboratories Refutes Claim of 25% Workforce Cost ReductionToday
Dr Reddy's Laboratories has denied reports claiming a 25% reduction in workforce costs. The company has issued a statement refuting this information, indicating that the reported cost-cutting measure is inaccurate.
neutral
Dr Reddy's Laboratories Denies Workforce Cost Reduction Claim13 hours ago
Dr Reddy's Laboratories has issued a statement denying claims of a 25% workforce cost reduction. The company has refuted this information, suggesting that the reported cost-cutting measure is inaccurate.
negative
Dr Reddy's Laboratories: Major Workforce Cost Reduction and Layoffs17 hours ago
Dr Reddy's Laboratories is implementing a significant downsizing initiative, aiming to cut workforce costs by nearly 25%. Senior executives and employees earning over ₹1 crore annually have been asked to resign. Voluntary retirement has been offered to R&D employees aged 50-55 years.
View more

Peer Comparison Compare Peers on Screener

Competitors LTP Market Cap (₹ Cr.) P/E Ratio Revenue (₹ Cr.) YoY Revenue Growth % Net Profit (₹ Cr.) YoY Profit Growth % RSI
Sun Pharmaceutical
1,687.55
#1 4,04,899.80
34.33
#1 49,887.20
12.06
#1 9,648
13.77
47.60
Divis Laboratories
5,589.30
1,48,378.40
71.83
8,184.00
0.89
1,600
#1 64.53
47.92
Cipla
1,463.05
1,18,158.10
23.68
26,520.70
14.17
4,155
47.38
50.89
Torrent Pharmaceuticals
3,129.00
1,05,899.60
56.84
10,785.70
11.59
1,656
13.54
45.29
Mankind Pharma
2,350.50
96,976.60
47.52
10,615.60
19.57
1,942
-16.38
48.68
Dr Reddys Laboratories
1,109.50
#6 92,582.80
#1 17.23
#3 28,905.40
#6 12.36
#2 5,578
#8 1.69
40.66
Lupin
1,969.25
89,904.30
31.34
20,141.50
#1 19.94
1,936
38.82
46.62
Zydus Life Science
868.85
87,426.60
19.27
19,831.50
13.82
3,831
29.92
44.56
Abbott
29,641.10
62,985.30
47.10
6,097.20
10.80
1,201
16.01
48.36
Aurobindo Pharma
1,082.45
62,868.90
17.83
29,559.20
17.55
3,169
-10.04
41.61

Automatic Screeners on ScanX

Community
10% near 52 Week Low
Growth Rate
Revenue Growth
12.36 %
Net Income Growth
23.75 %
Cash Flow Change
-22.83 %
ROE
1.96 %
ROCE
-3.56 %
EBITDA Margin (Avg.)
6.12 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Revenue
3,887
3,813
4,061
4,030
3,841
3,302
3,630
3,747
3,575
3,354
3,578
3,849
3,580
3,779
3,937
3,961
4,116
4,290
4,867
4,469
4,516
4,512
4,955
5,015
4,829
5,044
5,993
5,394
5,569
6,079
6,361
6,835
6,443
6,917
7,199
7,434
7,284
7,866
8,330
8,513
Expenses
3,271
2,765
2,888
2,996
3,313
2,855
2,989
2,859
3,021
3,010
2,890
3,041
2,990
2,968
3,058
3,060
3,211
3,117
3,749
4,686
3,500
3,305
3,755
4,403
3,715
4,211
4,427
4,123
5,024
4,292
4,433
4,851
4,781
4,696
4,894
5,214
5,283
5,566
5,962
6,108
EBITDA
616
1,048
1,173
1,034
528
447
640
888
553
344
687
808
590
812
879
901
905
1,174
1,118
-217
1,016
1,207
1,200
613
1,114
833
1,566
1,271
545
1,787
1,928
1,983
1,662
2,221
2,305
2,220
2,001
2,300
2,368
2,405
Operating Profit %
15 %
26 %
28 %
25 %
12 %
12 %
17 %
23 %
15 %
9 %
18 %
20 %
15 %
20 %
19 %
21 %
20 %
19 %
22 %
-7 %
21 %
25 %
23 %
11 %
21 %
14 %
23 %
23 %
8 %
18 %
30 %
28 %
24 %
30 %
29 %
28 %
25 %
27 %
26 %
27 %
Depreciation
0
203
224
235
277
244
262
267
254
259
270
272
276
279
279
290
287
289
313
287
274
292
317
311
309
284
294
294
293
302
309
324
316
353
376
374
368
381
397
471
Interest
23
28
22
16
17
15
13
16
20
22
22
17
18
20
21
24
25
30
30
15
23
23
25
19
30
19
23
22
32
35
31
42
35
37
35
39
59
60
76
82
Profit Before Tax
593
831
960
733
273
199
396
622
337
81
409
547
314
529
599
601
606
869
786
-506
736
901
873
295
815
556
1,273
974
259
1,468
1,614
1,638
1,329
1,850
1,917
1,829
1,605
1,883
1,917
1,874
Tax
74
184
185
147
150
45
87
130
-1
14
103
244
42
53
81
101
151
193
-321
33
-45
306
101
267
258
175
277
265
162
279
499
394
369
445
435
448
295
490
576
470
Net Profit
519
647
775
586
123
154
309
492
338
67
305
303
272
476
518
500
455
677
1,107
-538
781
595
772
28
557
380
996
709
97
1,189
1,114
1,244
960
1,405
1,482
1,381
1,310
1,392
1,342
1,404
EPS in ₹
30.45
37.99
45.42
34.34
7.19
9.06
18.64
29.72
20.38
4.02
18.42
18.25
16.39
28.69
31.22
30.16
27.45
40.81
66.78
-32.48
47.12
35.87
46.54
1.68
33.61
22.95
60.03
42.75
5.84
71.64
67.13
74.91
57.79
84.55
89.09
82.94
78.66
83.61
75.40
16.97
Above figures are in Rs. Crores

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Total Assets
18,598
20,384
21,817
22,544
22,466
23,225
26,617
29,747
32,285
38,864
Fixed Assets
5,377
6,563
6,931
6,968
7,191
6,850
8,206
8,122
9,219
10,426
Current Assets
11,877
11,794
9,684
10,498
11,110
12,599
14,550
17,782
20,426
24,805
Capital Work in Progress
529
772
3,325
3,471
2,934
1,535
1,565
1,293
1,030
1,419
Investments
2,102
3,833
2,110
2,298
2,587
2,678
2,212
2,616
4,986
4,931
Other Assets
10,590
9,216
9,452
9,808
9,754
12,162
14,634
17,716
17,050
22,088
Total Liabilities
18,598
20,384
21,817
22,544
22,466
23,225
26,617
29,747
32,285
38,864
Current Liabilities
6,821
6,347
8,420
6,894
5,897
7,214
8,104
9,766
8,572
9,588
Non Current Liabilities
1,923
1,467
1,135
3,079
2,545
412
871
769
427
1,021
Total Equity
9,853
12,570
12,262
12,572
14,024
15,599
17,642
19,212
23,286
28,255
Reserve & Surplus
9,768
12,485
12,179
12,489
13,994
15,616
17,755
19,289
23,330
28,271
Share Capital
85
85
83
83
83
83
83
83
83
83
Above figures are in Rs. Crores

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
-280
-47
-114
-124
-31
-27
1,286
3
-907
133
Investing Activities
-2,370
-1,610
-1,890
-1,483
-769
-495
-2,255
-2,565
-4,109
-4,034
Operating Activities
2,524
3,263
2,144
1,803
2,870
2,984
3,570
2,811
5,888
4,543
Financing Activities
-433
-1,700
-369
-444
-2,133
-2,516
-30
-242
-2,686
-376
Above figures are in Rs. Crores

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Promoter
26.74 %
26.73 %
26.72 %
26.72 %
26.72 %
26.71 %
26.71 %
26.70 %
26.70 %
26.69 %
26.66 %
26.65 %
26.65 %
26.65 %
26.64 %
26.64 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
42.21 %
0.00 %
44.49 %
42.27 %
41.75 %
40.08 %
DIIs
14.25 %
15.08 %
20.92 %
21.95 %
24.46 %
24.95 %
24.47 %
23.38 %
23.05 %
21.99 %
21.04 %
16.21 %
18.31 %
20.73 %
21.48 %
22.90 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
8.31 %
7.76 %
8.14 %
8.27 %
8.37 %
8.22 %
8.06 %
7.84 %
7.59 %
7.51 %
7.91 %
8.44 %
8.25 %
8.07 %
8.07 %
8.07 %
Others
50.70 %
50.43 %
44.22 %
43.07 %
40.45 %
40.12 %
40.76 %
42.08 %
42.66 %
43.80 %
2.18 %
48.69 %
2.30 %
2.29 %
2.06 %
2.30 %
No of Share Holders
2,21,107
2,23,309
2,55,720
2,42,376
2,63,803
2,55,300
2,59,271
2,46,788
2,32,715
2,46,769
2,43,445
2,57,794
2,55,500
2,67,694
3,10,403
4,03,669

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 20 20 20 20 25 25 30 40 40 0.00
Dividend Yield (%) 3.8 4.81 3.6 3.2 2.77 2.91 3.24 3.25 3.5 0.00

Corporate Action

Announcements

Disclosure Under Regulation 30 Of SEBI (LODR) Regulations 201513 hours ago
Disclosure Under Regulation 30 Of SEBI (LODR) Regulations 20159 days ago
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 01, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 01, 2025
Announcement under Regulation 30 (LODR)-Updates on AcquisitionMar 22, 2025
Board Meeting Intimation for Intimation Regarding Board Meeting And Trading Window ClosureMar 21, 2025
Closure of Trading WindowMar 21, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Mar 20, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMar 20, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 13, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 12, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 07, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMar 06, 2025
Disclosure Under Regulation 30 Of SEBI (LODR) Regulations 2015Feb 28, 2025
Disclosure Under Regulation 30 Of SEBI (LODR) Regulations 2015Feb 28, 2025
Disclosure Under Regulation 30 Of SEBI (LODR) Regulations 2015Feb 25, 2025
Disclosure Under Regulation 30 Of SEBI (LODR) Regulations 2015Feb 25, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSFeb 14, 2025
Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations 2015Feb 12, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 11, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 06, 2025
Disclosure Under Regulation 30 Of SEBI (LODR) Regulations 2015Feb 06, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 05, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 04, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 04, 2025
Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations 2015Feb 03, 2025
Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations 2015Feb 02, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJan 29, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 29, 2025
Intimation On Filing Of Form 6-K With US SEC For The Quarter And Nine Months Ended December 31 2024 Jan 24, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJan 24, 2025
Integrated Filing (Financial)Jan 24, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJan 24, 2025
Outcome of Board MeetingJan 23, 2025
Disclosure Under Regulation 30 Of SEBI (LODR) Regulations 2015 Jan 22, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 08, 2025
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jan 07, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 03, 2025
Announcement under Regulation 30 (LODR)-Credit RatingDec 27, 2024
Announcement under Regulation 30 (LODR)-AcquisitionDec 23, 2024
Board Meeting Intimation for Board Meeting Intimation For Approval Of Unaudited Financial Results Of The Company For The Quarter And Nine Months Ending On December 31 2024Dec 23, 2024
Closure of Trading WindowDec 23, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateDec 10, 2024
Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015Dec 06, 2024
Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015Dec 05, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationDec 03, 2024
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSDec 01, 2024
Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015Nov 28, 2024
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 28, 2024
Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015Nov 27, 2024

Technical Indicators

RSI(14)
Neutral
40.66
ATR(14)
Less Volatile
38.36
STOCH(9,6)
Neutral
32.44
STOCH RSI(14)
Neutral
21.49
MACD(12,26)
Bearish
-4.88
ADX(14)
Weak Trend
19.91
UO(9)
Bearish
49.67
ROC(12)
Downtrend And Accelerating
-8.33
WillR(14)
Neutral
-56.74
Bearish
5
Neutral
4
Bullish
0
raisewe are part of Raise Financial Services
Heart
built with love

for indians who love to invest & trade

Explore   |   Sitemap
Intraday Screeners
Fundamental Screeners
Price & Volume Screeners
Technical Screeners
Candlestick Screeners
Bullish Stocks Today
Bearish Stocks Today
Stocks Nearing 52W High & Low
Rise & Fall Stocks
Index
Sector
Stock Heatmap
Companies
About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.

© 2025 Moneylicious Securities Pvt. Ltd. All rights reserved.

Part of Raise Financial Services

Corporate Office: A-302, The Western Edge I, Off Western Express Highway, Borivali East, Mumbai – 400066, Maharashtra, India. Land Line: 022-43116666.